NVO - Inconsistent Insurance Coverage For Weight Loss Drugs - Novo Nordisk's GLP-1s Face Hurdles Despite Health Benefits | Benzinga
The recent expansion of Novo Nordisk A/S’s (NYSE:NVO) Wegovy’s (semaglutide) FDA approval has sparked a debate over insurance coverage for the drug.
However, despite its potential health benefits, some employers and health plans remain hesitant to cover the drug due to its high monthly price of $1,350 and uncertainties regarding patient adherence.
This expansion allows for a cost cap or savings guarantee, fostering accessibility for deserving patients.
Citing John Crable, Senior Vice President of Corporate Synergies, CNBC noted that the growing benefits associated with weight loss drugs may increase pressure on insurers to include them in standard insurance plans.
However, convincing insurers to do so may require more evidence of long-term efficacy and cost-effectiveness.
While approximately 50 million insured American adults ...